Suppliers and packagers for SANDIMMUNE

SANDIMMUNE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Novartis	SANDIMMUNE	cyclosporine	CAPSULE;ORAL	050625	NDA	Novartis Pharmaceuticals Corporation	0078-0240-15	30 BLISTER PACK in 1 PACKAGE (0078-0240-15) / 1 CAPSULE, LIQUID FILLED in 1 BLISTER PACK (0078-0240-61)	1990-03-02
Novartis	SANDIMMUNE	cyclosporine	CAPSULE;ORAL	050625	NDA	Novartis Pharmaceuticals Corporation	0078-0241-15	30 BLISTER PACK in 1 PACKAGE (0078-0241-15) / 1 CAPSULE, LIQUID FILLED in 1 BLISTER PACK (0078-0241-61)	1990-03-02
Novartis	SANDIMMUNE	cyclosporine	INJECTABLE;INJECTION	050573	NDA	Novartis Pharmaceuticals Corporation	0078-0109-01	10 AMPULE in 1 BOX (0078-0109-01) / 5 mL in 1 AMPULE (0078-0109-61)	1983-11-14

Sandimmune Pharmaceutical Drug Supply Chain Analysis

Last updated: February 19, 2026

This report details the critical suppliers for Sandimmune (cyclosporine), a vital immunosuppressant medication. The analysis covers active pharmaceutical ingredient (API) manufacturers, formulation and finished dosage form producers, and key excipient providers. The supply chain for Sandimmune is characterized by a limited number of specialized API manufacturers and a global network of generic drug producers, presenting both opportunities for supply assurance and risks associated with single-source dependency.

Who are the Primary API Manufacturers for Sandimmune?

The active pharmaceutical ingredient (API) for Sandimmune is cyclosporine. Cyclosporine is a cyclic undecapeptide produced by fermentation of specific fungal species. The production of high-purity cyclosporine API is a complex bioprocess requiring specialized fermentation technology and downstream purification.

Key manufacturers with significant historical or current involvement in cyclosporine API production include:

• Novartis AG: As the originator of Sandimmune, Novartis has been a primary producer and supplier of cyclosporine API. While Novartis has divested some API manufacturing capabilities, it maintains proprietary knowledge and likely retains some in-house production or has long-term contractual agreements for its supply.
• Specialized API Manufacturers: Several Contract Development and Manufacturing Organizations (CDMOs) and specialized API producers are known to manufacture cyclosporine. These include companies with expertise in fermentation-based API synthesis. Identification of specific current CDMO partners is proprietary information, but companies with broad fermentation capabilities and Good Manufacturing Practice (GMP) certifications are likely candidates.

The market for cyclosporine API is not as broadly populated as for many small molecule synthetic APIs due to the specialized nature of its production. This concentration increases reliance on a smaller pool of manufacturers.

How is Sandimmune Formulated into Finished Dosage Forms?

Sandimmune, specifically the oral solution formulation (Sandimmune Oral Solution), requires careful formulation to ensure cyclosporine's bioavailability, as it is poorly soluble in water. The formulation involves dissolving cyclosporine in a suitable oil-based vehicle, often with co-solvents and emulsifiers, to create a stable, administrable solution.

Key formulation and finished dosage form (FDF) manufacturers can be categorized as:

• Originator Manufacturer (Novartis AG): Novartis manufactures and markets the branded Sandimmune product. This involves proprietary formulation processes and quality control standards.
• Generic Manufacturers: A significant number of pharmaceutical companies globally produce generic versions of Sandimmune, including oral solutions and capsules. These manufacturers source cyclosporine API from various approved suppliers and then undertake their own formulation and FDF manufacturing.

Examples of companies that have marketed or may currently market generic Sandimmune products include, but are not limited to:

• Sandoz (a Novartis division, now independent): Historically a major player in generic pharmaceuticals, Sandoz has produced cyclosporine formulations.
• Teva Pharmaceutical Industries Ltd.: A large global generic manufacturer with a broad portfolio that has included immunosuppressants.
• Aurobindo Pharma Ltd.: An Indian multinational pharmaceutical company that manufactures and markets generic drug formulations.
• Mylan N.V. (now part of Viatris): Another significant generic pharmaceutical company.
• Sun Pharmaceutical Industries Ltd.: A global pharmaceutical company that manufactures and markets a wide range of generic and specialty products.

These generic manufacturers operate under strict regulatory oversight, ensuring their formulations meet bioequivalence standards compared to the originator product. The selection of API suppliers by these generic companies is critical and subject to regulatory approval.

What are the Key Excipients Used in Sandimmune Formulations?

The formulation of Sandimmune oral solution requires specific excipients to solubilize cyclosporine, enhance stability, improve palatability, and ensure appropriate absorption. Common excipient categories and examples relevant to cyclosporine oral solutions include:

• Solvents/Co-solvents: These are crucial for dissolving cyclosporine.
  • Medium-chain triglycerides (MCTs): Often used as the primary oil vehicle due to their lipophilic nature and good absorption properties. Examples include Captex® 300, Miglyol® 812.
  • Ethanol: May be used as a co-solvent to further enhance solubility and aid in the formulation process.
  • Propylene glycol: Another common co-solvent and humectant.
• Emulsifiers/Surfactants: To create a stable emulsion if a microemulsion or emulsion is desired, or to improve the dispersion of cyclosporine in the vehicle.
  • Polysorbates (e.g., Polysorbate 80): A common non-ionic surfactant used to stabilize oil-in-water or water-in-oil emulsions.
  • Lecithin: A natural phospholipid that can act as an emulsifier.
• Antioxidants: To prevent oxidation of cyclosporine or other formulation components, extending shelf life.
  • Alpha-tocopherol (Vitamin E): A natural antioxidant.
  • Ascorbyl palmitate: A fat-soluble form of Vitamin C.
• Flavoring Agents and Sweeteners: To mask the bitter taste of cyclosporine and improve patient compliance.
  • Artificial or natural flavors.
  • Sucralose, saccharin, or other approved sweeteners.
• Preservatives: To prevent microbial growth in multi-dose formulations.
  • Parabens (e.g., methylparaben, propylparaben): Though usage is declining due to regulatory scrutiny and patient preference.
  • Sorbic acid or potassium sorbate.

Major global excipient manufacturers supplying these categories include:

• BASF SE: A broad supplier of a wide range of pharmaceutical excipients, including solvents, emulsifiers, and preservatives.
• Croda International Plc: Specializes in high-purity excipients, including emulsifiers, emollients, and solubilizers.
• Kerry Group: Offers a range of functional ingredients and excipients for pharmaceutical applications.
• Ashland Global Holdings Inc.: Provides specialty ingredients including solvents, emulsifiers, and film-forming agents.
• Ineos Solvents: A leading producer of solvents such as ethanol.

The selection and sourcing of these excipients are critical for the stability, efficacy, and safety of the final Sandimmune product. Manufacturers must ensure their excipient suppliers meet stringent GMP and pharmacopoeial standards.

What are the Regulatory Considerations for Sandimmune Suppliers?

Suppliers for Sandimmune, regardless of their position in the supply chain (API, FDF, excipient), are subject to rigorous regulatory oversight by health authorities worldwide, including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others.

Key regulatory considerations include:

• Active Pharmaceutical Ingredient (API) Suppliers:
  • Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory agencies. These confidential documents contain detailed information about the manufacturing process, controls, and facilities. Pharmaceutical companies referencing a DMF in their drug applications must have a Letter of Authorization (LOA) from the API manufacturer.
  • Good Manufacturing Practices (GMP): API manufacturing facilities must comply with cGMP guidelines. Regular inspections by regulatory bodies are a prerequisite for continued approval.
  • ICH Guidelines: Compliance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines (e.g., ICH Q7 for API GMP) is essential.
  • Quality Agreements: Formal quality agreements between the API supplier and the FDF manufacturer are mandatory to define responsibilities for quality control, change management, and issue resolution.
• Finished Dosage Form (FDF) Manufacturers:
  • Marketing Authorization Applications (MAAs) / New Drug Applications (NDAs) / Abbreviated New Drug Applications (ANDAs): FDF manufacturers must obtain approval to market their Sandimmune products. This involves submitting comprehensive dossiers detailing the formulation, manufacturing process, analytical methods, stability data, and bioequivalence studies (for generics).
  • GMP Compliance: FDF manufacturing sites must adhere to cGMP regulations.
  • Supply Chain Integrity: FDF manufacturers are responsible for the entire supply chain, including the quality of sourced API and excipients. Robust supplier qualification and monitoring programs are required.
  • Post-Market Surveillance: Ongoing monitoring of product quality, adverse events, and compliance with labeling requirements is necessary.
• Excipient Suppliers:
  • Pharmacopoeial Compliance: Excipients must meet the quality standards defined in relevant pharmacopoeias (e.g., United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), Japanese Pharmacopoeia (JP)).
  • GMP for Excipients: While not always as strictly regulated as API GMP, many regulatory bodies and industry standards (e.g., EXCiPACT) promote GMP principles for excipient manufacturers to ensure quality and traceability.
  • Supplier Audits and Qualification: FDF manufacturers must audit and qualify their excipient suppliers to ensure consistent quality and compliance.
  • Change Control: Notification and approval of any significant changes in excipient manufacturing processes are critical.

The regulatory landscape for pharmaceuticals is dynamic. Suppliers must remain vigilant regarding evolving guidelines and potential new requirements from global health authorities.

What are the Potential Supply Chain Risks and Mitigation Strategies for Sandimmune?

The supply chain for Sandimmune, particularly for the cyclosporine API, presents several potential risks that could impact availability and cost.

Key Risks:

• API Manufacturing Concentration: The limited number of specialized cyclosporine API manufacturers creates a risk of supply disruption if one or more key producers face manufacturing issues, regulatory action, or decide to exit the market. This can lead to shortages and price volatility.
• Dependence on Fermentation Technology: Cyclosporine's production via fermentation is a complex, multi-step biological process that is more challenging to scale up and control compared to traditional chemical synthesis. This inherent complexity can lead to batch-to-batch variability and longer lead times.
• Geopolitical and Economic Factors: Global supply chains are susceptible to disruptions from geopolitical instability, trade disputes, natural disasters, and pandemics, affecting raw material availability, transportation, and manufacturing operations.
• Quality Control and Regulatory Non-Compliance: A failure in quality control at any stage of the supply chain, from API to excipients, can lead to product recalls, regulatory actions, and reputational damage, impacting the entire product lifecycle.
• Intellectual Property (IP) Landscape: While Sandimmune (cyclosporine) is an established drug, new process patents or formulation patents for specific delivery systems could emerge, impacting generic competition and supply options.
• Cost Pressures: Generic drug markets are highly competitive, leading to intense price pressure. This can impact the profitability of API and FDF manufacturers, potentially leading to underinvestment in capacity or quality systems.

Mitigation Strategies:

• Supplier Diversification: For FDF manufacturers, establishing relationships with multiple qualified API suppliers, where feasible, is the most effective strategy to mitigate single-source dependency. This requires significant investment in supplier qualification and validation.
• Strategic Stockpiling: Maintaining strategic reserves of critical raw materials (API and key excipients) and finished goods can buffer against short-term supply disruptions. This requires careful inventory management to avoid obsolescence and manage carrying costs.
• Robust Supplier Qualification and Auditing Programs: Implementing rigorous processes for vetting, qualifying, and regularly auditing all suppliers (API, excipients, packaging) ensures adherence to quality standards and regulatory requirements. This includes site audits, review of quality systems, and testing of incoming materials.
• Long-Term Contracts and Partnerships: Securing supply through long-term contracts with key suppliers can provide greater price stability and guaranteed supply volumes. Collaborative partnerships can also foster greater transparency and joint problem-solving.
• Supply Chain Mapping and Visibility: Thoroughly mapping the entire supply chain, including sub-tier suppliers, provides a clearer understanding of potential vulnerabilities and allows for proactive risk assessment. Real-time supply chain visibility tools can aid in monitoring and responding to disruptions.
• Process Optimization and Technology Adoption: For API manufacturers, continuous investment in process optimization, yield improvement, and potentially newer manufacturing technologies can enhance efficiency, reduce costs, and improve supply reliability.
• Regulatory Intelligence and Compliance: Staying abreast of evolving regulatory requirements and ensuring continuous compliance with GMP and other standards is paramount. Proactive engagement with regulatory agencies can help anticipate and address potential issues.
• Contingency Planning: Developing detailed contingency plans for various disruption scenarios (e.g., natural disasters, plant shutdowns, geopolitical events) allows for swift and coordinated responses.

Key Takeaways

The Sandimmune supply chain is characterized by specialized, fermentation-based API production, leading to a concentrated supplier base. Generic competition is significant, with numerous FDF manufacturers relying on a global network of excipient suppliers. Key risks include API supply concentration, fermentation complexity, and global geopolitical/economic factors. Mitigation strategies focus on supplier diversification, strategic stockpiling, robust quality systems, and strong supplier relationships. Regulatory compliance is paramount at every tier of the supply chain.

FAQs

What is the primary challenge in sourcing cyclosporine API?

The primary challenge is the complex fermentation-based manufacturing process, which requires specialized infrastructure and expertise, leading to a limited number of qualified API producers.

How do generic Sandimmune manufacturers ensure API quality?

Generic manufacturers must qualify their API suppliers through rigorous audits, review of Drug Master Files (DMFs), and routine testing of incoming API batches to ensure they meet pharmacopoeial standards and regulatory requirements.

Can excipient availability impact Sandimmune formulation?

Yes, the availability and quality of specific excipients, such as specialized solvents and emulsifiers required for cyclosporine's poor solubility, are critical for the successful formulation and stability of Sandimmune oral solutions.

What is the role of regulatory bodies in the Sandimmune supply chain?

Regulatory bodies like the FDA and EMA oversee all aspects of the supply chain, from API manufacturing (GMP, DMFs) to finished drug product approval (ANDA/MAA, GMP) and post-market surveillance, ensuring product safety and efficacy.

How can pharmaceutical companies prepare for potential Sandimmune shortages?

Companies can prepare by diversifying API suppliers where possible, maintaining adequate safety stock of API and finished goods, establishing strong quality agreements with suppliers, and implementing comprehensive supply chain risk management plans.

---

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files. Retrieved from https://www.fda.gov/drugs/drug-master-files [2] European Medicines Agency. (n.d.). Active substances. Retrieved from https://www.ema.europa.eu/en/human-regulatory/research-and-development/non-proprietary-name-active-substance-initiative/active-substances [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Quality Guidelines. Retrieved from https://www.ich.org/page/quality-guidelines [4] United States Pharmacopeia. (n.d.). About USP. Retrieved from https://www.usp.org/about [5] Pharmaceutical Excipients. (n.d.). EXCiPACT Certification. Retrieved from https://excipact.org/